| Metric | Value (₹ Cr) | vs Q1 FY27 |
|---|---|---|
| Revenue | 279.93 | 28.3% |
| Total Income | 280.04 | 28.2% |
| Expenditure | 216.00 | 7.5% |
| PBT | 64.04 | 265.3% |
| Net Profit | 51.72 | 267.8% |
| OPM | 32.69% | 11.97pp |
| NPM | 18.47% | 12.03pp |
| EPS | 8.20 | 266.1% |
₹280 Crore Quarter Masks Milestone Lumpiness; Guidance Signals Slowdown Ahead
Q2 revenue surged 43% YoY and PAT nearly tripled, but ₹53 crore of the quarter was driven by a one-time DCV milestone. Organic API growth of 16% is solid—yet management's FY27 guidance of 20% revenue growth is oddly conservative, and ₹1,000+ crore in planned capex carries meaningful execution risk.
₹279.9 Cr
+43% YoY
~16%
ex ₹53 Cr milestone
₹51.7 Cr
+169% YoY
~0.44x
₹113 Cr spend · ₹1,000+ Cr planned
On the headline, this looks like a blowout: revenue up 43%, profit up 169%. But peel back the layers and the story is more measured. Of the ₹279.9 crore in Q2 revenue, ₹53 crore flowed from a one-time DCV milestone recognition—leaving organic API business growth of roughly 16%, solid but not extraordinary. The profit pop is real, but it reflects operating leverage on a milestone-heavy quarter. The real tension sits in management's guidance: they've promised ~20% revenue growth and ~25% EBITDA growth for the full year, a notably conservative target given Q2's 43% print and the size of deals already signed (DCV, alternate protein CDMO, insulin). That gap—between what they delivered and what they're guiding—is worth examining.
Where the growth came from
The API segment—steroid hormones, complex injectables, contract manufacturing—grew to ₹227 crore in Q2, up 16% organically year-on-year. That's a healthy mid-teens clip. The kicker is the ₹53 crore DCV (dual-chamber vial) milestone, recognition of development and manufacturing rights handed over to a US partner. It's real revenue, already invoiced and settled in the quarter, but it's not repeatable at that scale. Management noted that the balance of FY27 milestone revenue will be spread across Q3 and Q4, though they declined to quantify the exact quarterly cadence—citing client confidentiality. For a foundation, assume the milestone tail is lighter than Q2's ₹53 crore, and that the API business carries the quarterly load going forward.
Q2 revenue ₹280 Cr, up 43% YoY
Delivered ₹279.9 Cr; 43% growth confirmed
Supported
EBITDA 88% growth in Q2
INR94 Cr vs INR50 Cr prior (adjusted for IPO); verified
Supported
PAT 169% YoY growth
INR51.7 Cr vs prior ~₹30.6 Cr implied; confirmed
Supported
FY27 guidance: 20% revenue growth, 25% EBITDA growth
Q2 showed 43% revenue, 88% EBITDA; guidance is 54% below Q2 revenue growth
Overstated (implies slowdown)
Why the guidance is oddly conservative
The paradox: Q2 printed at 43% revenue growth, yet management is guiding FY27 at just 20%. That's not a slowdown risk—it's guidance that assumes one. In isolation, that reads defensive, possibly prudent. But the call revealed concrete catalysts already in the pipeline: a DCV contract with a US partner (INR 300 million addressable market in the US alone), a 750 KL fermentation CDMO deal with a European alternate-protein customer, an insulin facility in late-stage validation with a take-or-pay domestic contract expected in Q4, and a vegan vitamin D3 facility qualification target by end-FY27. The company has also raised the fermentation capex from an earlier 600 KL to 750 KL, signaling confidence in near-term CDMO adoption. So why not raise FY27 guidance? Management's hedging reflects two constraints: (1) Regulatory approval timing is uncertain. Insulin ANDA filed Sep 2026; FDA inspection + approval targeted calendar 2027, but delays are common. DCV FDA approval also calendar 2027, so no revenue recognition until approvals land. (2) Capex intensity will compress margins if revenue doesn't accelerate. Planned capex across DCV, fermentation, insulin, and vitamin D3 is ₹1,000+ crore—roughly 19x the quarterly PAT. Even with customer co-funding, the internal capex burden is material, and near-term FCF will tighten. Conservative guidance protects against regulatory slip and capex overruns.
What changed on this call
Fermentation capex raised: 600 KL → 750 KL Phase 1 for alternate protein (Europe customer)
Alternate protein (fermentation CDMO) agreement signed; long-term, customer co-funded
Insulin facility ANDA filed Sep 2026 (expedited track); FDA inspection + approval targeted calendar 2027
Vegan Vitamin D3 plant qualification target end-FY27; pricing strategy not yet final
API price pressure acknowledged across steroid hormones, solvent cost pressures (Iran, sanctions); offset by volume and geography mix
None of these are reversals. All are incremental upgrades—fermentation getting bigger, regulatory pipelines staying on track—or downgrades (API price pressure staying hot). The earnings call confirmed no prior-period misses. Since this is Symbiotec's first earnings call post-IPO, there's no track record of guidance beats/misses to weigh.
The bull-bear ledger
Q2 execution strong: 43% revenue growth, 88% EBITDA growth, flat OPM (stable margins despite scaling)
Regulatory approvals on track: 4 major inspections cleared H1 with zero findings; EIR received for both Rau and Pithampur SEZ facilities
New verticals de-risked: DCV already signed with milestone revenue visible; insulin ANDA in-flight; fermentation capacity pre-committed (customer co-funded)
API moat widening: 60+ steroid/hormone molecules filed, 25 CEP approvals, backward integration reducing solvent cost exposure
Milestone revenue is one-time; organic API growth 16% is solid but masks headline 43% print. FY27 guidance implies slowdown.
Capex intensity extreme: ₹1,000+ Cr planned capex vs ₹51.7 Cr Q2 PAT (19x ratio). Near-term FCF will compress despite strong profitability.
Regulatory approval timelines are key gating events. Insulin and DCV FDA approvals targeted calendar 2027, but delays are common in complex injectables/biologics.
API price pressure persists; management acknowledged ongoing erosion in steroid hormones. Volume/mix gains so far offset, but not guaranteed to hold.
New verticals unproven at scale: fermentation CDMO, insulin, vegan D3 are all greenfield for Symbiotec. Execution track record is zero.
Risks, ranked by how much they should concern a holder
Capex execution & FCF squeeze
High₹1,000+ Cr capex is 19x quarterly PAT. Even with customer co-funding, internal capex will compress FCF through FY27–FY28. If any vertical slips (fermentation scale-up, insulin timeline, vegan D3 ramp), capex ROI extends further. Near-term debt could rise.
Regulatory approval delays (FDA insulin/DCV, EMA alternate protein)
HighInsulin ANDA filed Sep 2026, FDA inspection + approval targeted calendar 2027. DCV FDA approval also calendar 2027. Delays are common in complex injectables/biologics. If approvals slip into FY28, material revenue and capex ROI timelines extend by 1–2 quarters.
Milestone revenue front-loading; organic growth slowdown
Medium₹53 Cr DCV milestone in Q2 may be the peak quarterly hit. If Q3/Q4 milestones are lighter and organic API growth doesn't accelerate, guidance miss is material. FY27 guidance of 20% revenue would not be achieved.
Customer concentration in CDMO (alternate protein)
Medium750 KL Phase 1 expansion is anchored to one European customer's alternate protein agreement. If customer scales slower or cancels, capex ROI dilutes and utilization drops.
API price pressure persisting; margin compression risk
MediumSteroid hormone APIs face ongoing price erosion due to Iran sanctions, solvent costs, competition. Management acknowledged this. Volume/geography mix has offset to date, but if this fails, organic growth will decelerate further.
How the street is positioned
Price action: Symbiotec trades at ₹1,638 as of Nov 12, just 1.03% below its all-time high of ₹1,655. The stock has rallied from a 52-week low of ₹985.6, a gain of 66% off the lows. Volume is increasing. On the surface, the post-result reaction looks positive—the stock holding near ATH suggests the market is comfortable with the delivery and guidance. But the RSI is at 74.9, squarely in overbought territory (>70). This signals that short-term momentum has run hard and pullback risk is rising. Combined with the ATH proximity, the risk/reward is tilted toward caution. A stumble in FY27—guidance miss, capex overrun, regulatory delay—could spark a sharp reversion.
Flows & ownership: Bulk/block deals over the last six months show consistent buying pressure from JUNOMONETA FINSOL, ELIXIR WEALTH, MICROCURVES TRADING, and NK SECURITIES. No material promoter or insider-linked selling near the highs. That's bullish from a flow perspective. But none of these names are mega-anchors; the deals are scattered. Large foreign institutional inflows are not visible in the data, which is a mild yellow flag for a small-cap pharma play at ATH.
Valuation context: The stock is at its highs. For a company guiding 20% FY27 revenue growth and 25% EBITDA growth—healthy, but not blowout numbers—trading at ATH with RSI overbought is a caution flag. The capex intensity (19x PAT) will also pressure near-term EPS. Valuations typically re-rate down for capex-heavy businesses in growth mode, not up. If the market reprices Symbiotec on capex reality or regulatory delay, downside could be 15–20%.
The debate
What to watch next
1 · Q3 FY27 organic API growth (excl. milestone)
If organic API growth decelerates below 10% in Q3, the 16% Q2 print may have been a one-off, signaling weakness into FY28. If it holds at 12–15%, the guidance of 20% FY27 revenue growth is credible.
2 · FDA insulin ANDA progress; inspection timeline
ANDA filed Sep 2026, targeted for FDA inspection + approval in calendar 2027. Any delay into Q1 FY28 or later pushes insulin revenue into FY28, compressing FY27 beat potential and extending capex ROI by 1–2 quarters.
3 · Fermentation Phase 1 commissioning & early utilisation
750 KL Phase 1 is targeted for end-FY27 qualification. Any delay or lower-than-expected customer ramp into FY28 would signal capex ROI risk and raise questions on the ₹1,000+ Cr capex commitment.
The number to track
Watch organic API growth (excluding milestones) as the key litmus test. Q2's 16% was solid. If Q3 and Q4 print at 12–15%, FY27 guidance of 20% is achievable but tight. If organic growth drops below 10%, the company will likely miss full-year guidance, and the near-term re-rating risk is material.
Symbiotec delivered a strong Q2 on the headline, but the quarter was milestone-heavy and the guidance for FY27 is cautious relative to the delivery. The real story is execution on capex-intensive new verticals (DCV, insulin, fermentation CDMO) against regulatory timelines that are uncertain. Management is credible, but the stock is priced for perfection—trading at ATH with RSI overbought. This is steady progress, not a step-change, and valuations don't typically re-rate up for capex-heavy growth phases. Hold here and wait for either (a) a pullback to ₹1,350–₹1,450 to add, or (b) clarity on regulatory timelines and capex ROI to revisit. The risk/reward is not favourable at current levels.